Mark Ayers
YOU?
Author Swipe
One-year outcomes of patients with hypertrophic cardiomyopathy according to levels of inflammatory biomarkers Open
Background Hypertrophic cardiomyopathy (HCM) is a vastly heterogeneous sarcomere disorder unified by maximal left ventricular (LV) thickness increases. The lifetime relative risk of morbidity in HCM is four-fold higher than in the general …
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782 Open
AEs were consistent with the established safety profile of first-line pembrolizumab plus chemotherapy in NSCLC. Baseline bTMB did not show evidence of an association with efficacy.
View article: Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer
Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer Open
Objectives Prevalence of tumor PD-L1 expression in extensive-stage small-cell lung cancer (ES-SCLC) is variable, and data on PD-L2 expression are limited. The prognostic values of these biomarkers are not well understood. The current study…
Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Purpose:To explore relationships between biological gene expression signatures and pembrolizumab response.Experimental Design:RNA-sequencing data on baseline tumor tissue from 1,188 patients across seven tumor types treated with pembrolizu…
Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Purpose:To explore relationships between biological gene expression signatures and pembrolizumab response.Experimental Design:RNA-sequencing data on baseline tumor tissue from 1,188 patients across seven tumor types treated with pembrolizu…
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Table S1 from Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Open
Supplementary Table S1 from Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Data from Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Open
Purpose: Molecular classification of breast cancer has been proposed based on gene expression profiles of human tumors. Luminal, basal-like, normal-like, and erbB2+ subgroups were identified and were shown to have different prognoses. The …
Supplementary Data from Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy Open
Supplementary Tables S1, S2; Supplementary Figures S1, S2, S3, S4
Supplementary Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Data from Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Open
Purpose: Molecular classification of breast cancer has been proposed based on gene expression profiles of human tumors. Luminal, basal-like, normal-like, and erbB2+ subgroups were identified and were shown to have different prognoses. The …
Data from Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy Open
Purpose:Molecular profiling of large databases of human tumor gene expression profiles offers novel opportunities for informing decisions in clinical development programs.Experimental Design:Gene expression profile of programmed death liga…
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Data from Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy Open
Purpose:Molecular profiling of large databases of human tumor gene expression profiles offers novel opportunities for informing decisions in clinical development programs.Experimental Design:Gene expression profile of programmed death liga…
Supplementary Table S1 from Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Open
Supplementary Table S1 from Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Supplementary Data from Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy Open
Supplementary Tables S1, S2; Supplementary Figures S1, S2, S3, S4
Supplementary Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Data from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types Open
Supplementary Figure from Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Biomarkers predictive of response to pembrolizumab in head and neck cancer Open
Background We performed an integrated biomarker evaluation in pembrolizumab‐treated patients with R/M HNSCC enrolled in KEYNOTE‐012 or KEYNOTE‐055. The relationship between biomarkers and HPV status was explored. Methods We evaluated PD‐L1…
View article: Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC Open
These findings support pembrolizumab-combination as first-line treatment in patients with metastatic NSCLC and do not suggest the utility of tTMB, STK11, KEAP1, or KRAS mutation status as a biomarker for this regimen.
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer Open
Aim: Investigate the relationship between response to pembrolizumab and expression of the 18-gene T cell-inflamed gene expression profile (TcellinfGEP) or PD-L1 combined positive score (CPS) in esophageal cancer. Materials & methods: This …
View article: Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma Open
Background To characterize genomic determinants of response to pembrolizumab in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 study. Methods Associations between biomarkers (tumor mutational bu…